亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A Dose-Finding Study of Zoledronate in Hypercalcemic Cancer Patients

医学 癌症 内科学 肿瘤科
作者
J.J. Body,Alain H. Lortholary,Gilles Romieu,Anne-Marie Vigneron,J. Ford
出处
期刊:Journal of Bone and Mineral Research [Oxford University Press]
卷期号:14 (9): 1557-1561 被引量:160
标识
DOI:10.1359/jbmr.1999.14.9.1557
摘要

Zoledronate is a new heterocyclic imidazole bisphosphonate that is the most potent bisphosphonate administered in humans because it is 100-850 times more potent than pamidronate, according to in vitro or animal models of bone resorption. We conducted an open-label, dose-finding, single-dose phase I study in tumor-induced hypercalcemia (TIH), which has been similarly used as a model to determine the active doses of other bisphosphonates. The primary objective was to determine, with a dose escalation schedule, two nontoxic dose levels of zoledronate able to induce normocalcemia in at least 80% of patients with TIH after rehydration (corrected Ca for albumin levels >/=2.75 mmol/l). Based on estimates of potency, the starting dose was 0.002 mg/kg, and further tested doses were 0. 005, 0.01, 0.02, and 0.04 mg/kg. To obtain a more precise estimate of the response rate, we treated 10 more patients at the highest of the two effective dose levels. The median infusion time of zoledronate was 30 minutes. Thirty out of the 33 treated patients were evaluable for efficacy. Thirty percent of the patients had breast cancer and 54% had metastatic bone involvement. For all groups combined, mean Ca levels at baseline was 3.0 mmol/l. The two effective dose levels were 0.02 mg/kg and 0.04 mg/kg. Five out of five patients became normocalcemic after 0.02 mg of zoledronate/kg and 14 out of 15 after 0.04 mg of zoledronate/kg. The success rate of the latter dose was thus 93% (95% confidence interval [CI] 68-100%). At this dose, the first day of normocalcemia was day 2 or 3 for all but one patient. The duration of normocalcemia for the two effective doses could be assessed in nine patients; seven patients remained normocalcemic throughout the trial (32-39 days). The fall in serum Ca was accompanied by a marked fall in fasting urinary Ca excretion. Zoledronate was well tolerated: 7 out of 33 patients developed transient hypophosphatemia, and 3 developed transient hypocalcemia. The only clinically detectable side effect was an increase in body temperature occurring in 10 (30%) patients. In summary, very low doses of zoledronate (0.02 mg/kg and 0.04 mg/kg, i. e., 1.2 mg and 2.4 mg for a 60-kg individual, respectively) administered by a short-time infusion effectively treated patients with TIH. The fall in serum Ca was rapid, and normocalcemia was often maintained for several weeks. Zoledronate was well tolerated. Future trials will determine whether prolonged treatment with this potent compound can have greater effects on the skeletal morbidity rate in patients with tumor bone disease than can be achieved with currently available bisphosphonates.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Flynn发布了新的文献求助10
4秒前
清汐完成签到 ,获得积分10
4秒前
阿腾发布了新的文献求助10
5秒前
9秒前
loii的应助被务实的小凡采纳,获得50
9秒前
小马甲的应助被阿腾采纳,获得10
10秒前
12秒前
12秒前
Flynn完成签到,获得积分10
13秒前
陈鑫龙完成签到 ,获得积分10
13秒前
14秒前
liugaoleng完成签到 ,获得积分10
16秒前
16秒前
17秒前
巨型肥猫发布了新的文献求助10
17秒前
111发布了新的文献求助10
18秒前
瑩火虫完成签到 ,获得积分10
19秒前
Saturday完成签到,获得积分10
20秒前
tt完成签到 ,获得积分10
21秒前
21秒前
CTShih发布了新的文献求助10
21秒前
21秒前
Ephemeral完成签到 ,获得积分10
22秒前
23秒前
悦耳的成危完成签到,获得积分10
24秒前
天天快乐的应助被lalala采纳,获得10
27秒前
吃皮完成签到 ,获得积分10
27秒前
CAOHOU的应助被111采纳,获得10
28秒前
wangheng完成签到,获得积分20
29秒前
159357完成签到,获得积分10
32秒前
33秒前
159357发布了新的文献求助30
36秒前
37秒前
粗心的涔雨完成签到,获得积分10
40秒前
Sissi发布了新的文献求助10
42秒前
44秒前
45秒前
含糊的盼波完成签到,获得积分10
47秒前
星矢一道完成签到 ,获得积分10
47秒前
LAN完成签到,获得积分10
48秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179656
求助须知:如何正确求助?哪些是违规求助? 9569921
关于积分的说明 21807706
捐赠科研通 7775141
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2557032
邀请新用户注册赠送积分活动 2478778